NCT06671392 - A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients with Hypertension | Biotech Hunter

Enrollment

192

Participants

Timeline

Start Date

February 24, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions

Essential Hypertension

Interventions

DRUG

DWC202405

5/20mg, 1 tablet, Oral, Once a day

DRUG

DWC202405, DWC202314

5/20mg + 1.5mg, 1 tablet, Oral, Once a day

DRUG

DWC202405, DWC202314P

5/20mg + 1.5mg, 1 tablet, Oral, Once a day

DRUG

DWC202313, DWC202314

10/40mg + 1.5mg, 1 tablet, Oral, Once a day

DRUG

DWC202313, DWC202314P

10/40mg + 1.5mg, 1 tablet, Oral, Once a day

Trial Locations (1)

RECRUITING

Korea University ANAM Hospital, Seoul